Clinical Trial

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Name: Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors — clinical trial record (NCT07584954)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

Trial Details

NCT Number	NCT07584954
Lead Sponsor	Jun Zhou Collaborators: Fudan University, Hunan Cancer Hospital, Fujian Cancer Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shandong Cancer Hospital and Institute, Anyang Tumor Hospital
Conditions	Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Enrollment	90 participants
Start Date	2024-06-18
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-13